Menu
This week, seven biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy"). More
This week, seven biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy"). More
Biotech giant AMGN has a nice benefit Amgen stock in that it pays a dividend. With a low payout ratio, investors should look for increases in the future. More
Healthcare stocks have outperformed in recent years, but investors need to be selective with valuations that now are at richer levels. More
Amgen released earnings that put a smile on investor's faces, and Amgen stock looks like a solid buy for the long term More
Merck is one the most high profile companies in the pharmaceutical industry, and Merck stock is well worth a look for investors. I rate it a buy today. More
Ignore most of the Wall Street bluster about defensive stocks. Instead, buy these two stocks which have solid fundamentals backing them up. More
Sponsored By:
